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Tumor Treatment,’’ combines the presentations and
discussions from two successive International Symposia
held in conjunction with the European Society for
Medical Oncology (ESMO) annual congresses in 2000
and 2002, which assessed the interaction of hemoglobin
(Hb) levels with tumor hypoxia and treatment out-
comes. The ﬁrst symposium (Hamburg, Germany, late
2000) provided a detailed overview of the causes of
tumor hypoxia and its impact on treatment eﬃcacy and
survival. The faculty also explored ongoing research
concerning the beneﬁts of reversing anemia with
recombinant human erythropoietin (rHuEPO, epoetin
alfa) as a means of correcting anemic hypoxia in solid
tumors and improving clinical outcome. During the
second symposium (Nice, France, October 2002),
faculty members discussed advanced strategies for use
of epoetin alfa after providing an update on the discus-
sions of the ﬁrst symposium.
Tumor hypoxia has far-reaching clinical implications,
including increased tumor aggressiveness, increased
resistance to radiotherapy and chemotherapy, and
decreased patient survival, according to research repor-
ted by Professor Peter Vaupel [1]. One of the major
pathogenetic mechanisms for development of tumor
hypoxia is anemia, a common problem associated with
cancer as well as its various treatments. Professor
Ju¨rgen Dunst summarized the process by which anemia
may worsen tumor tissue oxygenation, thereby pro-
moting tumor hypoxia, and reviewed clinical studies
demonstrating that a decrease in Hb level during radio-therapy strongly increases the risk of treatment failure.
Conversely, administration of epoetin alfa during
neoadjuvant radiotherapy rapidly increases Hb levels
and may increase the eﬃcacy of treatment [2]. As
described by Professor Simon Van Belle, the pretreat-
ment Hb level is an important prognostic factor in both
hematologic and solid malignancies. In support of the
clinical studies, preclinical data have shown that
increasing pretreatment Hb levels can induce an
enhanced response to various cytotoxic therapies in
models of implanted animal tumors or human cancer
xenografts [3–6].
These ﬁndings raise the intriguing possibility that
correcting anemia may improve survival of cancer
patients. Clinical research is beginning to address this
issue. Professor Matti Aapro described the results of a
recently published placebo-controlled, double-blind
study in patients receiving non platinum chemo-
therapy regimens, which showed that epoetin alfa
signiﬁcantly decreased transfusion requirements,
signiﬁcantly increased Hb levels, and provided sig-
niﬁcantly greater improvements in cancer- and anemia-
speciﬁc quality-of-life (QOL) domains [7]. In addition,
study results suggested a survival advantage for patients
who received epoetin alfa versus placebo. These results
must be interpreted with caution, however, because the
study was neither designed nor powered to assess
survival.
Dr Mathias Freund noted that epoetin alfa possesses
biological activities other than erythropoietic eﬀects.
For example, epoetin alfa appears to have central ner-
vous system eﬀects according to Dr Anthony Cerami.
The erythropoietin receptor is abundantly expressed in
brain capillaries, representing a possible route for cir-
culating erythropoietin to enter the brain. Current
research suggests that epoetin alfa may have neuropro-
tective and anti-apoptotic eﬀects in the CNS, perhaps
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[8,9]. Astrocytes and neurons also express erythro-
poietin [10]; hence, local erythropoietin production may
be even more important than erythropoietin transported
through the blood-brain barrier. The CNS-related data are
certainly intriguing, and suggest potential therapeutic
uses for epoetin alfa in CNS disorders such as ischemic
stroke, trauma, and cognitive dysfunction [11].
In addition to evaluating the possible expanded bene-
ﬁts of epoetin alfa treatment, recent research has
focused on a once-weekly dosing regimen that improves
convenience for patients and physicians while main-
taining the established eﬃcacy of thrice-weekly dosing.
Clinical data consistently show that the once-weekly
epoetin alfa-dosing regimen is eﬀective and safe,
according to Dr Paul Sabbatini [12,13]. Moreover,
early-intervention studies have demonstrated that insti-
tution of once-weekly epoetin alfa before the onset
of anemia may help maintain normal Hb levels in
breast cancer patients who are undergoing adjuvant or
neo-adjuvant chemotherapy, thereby maintaining
or improving QOL [14,15]. Other epoetin alfa dosing
strategies are under investigation with the ultimate
goal of optimizing anemia management and patient
convenience.
Professors Bugat and Vaupel reviewed the evidence
indicating that higher Hb levels may often lead to better
outcomes, as well as the clinical data regarding the
beneﬁts of treating cancer patients with epoetin alfa, all
of which support revising the current practice to main-
tain Hb levels of at least 12 g/dl [16].
Overall, the symposia presentations highlighted some
of the notable improvements epoetin alfa has made
possible in the areas of anemia and oncology, and
underscored the need for continued investigation of this
agent to allow determination of its full therapeutic
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